SU6656
目录号 : GC17500Inhibitor of Src kinases
Cas No.:330161-87-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SU6656 is a small-molecule, potent and selective inhibitor of Src tyrosine kinases.
Src (proto-oncogene tyrosine-protein kinase) is a non-receptor protein tyrosine kinase family including 9 members and promotes survival, angiogenesis, and proliferation and invasion pathways.
In NIH 3T3 cell, SU6656 inhibits PDGF-/Src-driven mitogenesis and PDGF-stimulated c-Myc induction. [1] In UT-7/TPO, SU6656 cause ceased cell division but DNA continues accumulating by endomitosis. It also increased CD41 and CD61 expression on the cell surface in. [2] SU6656 in combination with radiation decrease clonogenic survival of endothelial cells. Src family kinase inhibition by SU6656 attenuated radiation-induced Akt phosphorylation and increased radiation-induced apoptosis and vascular endothelium destruction. [3]
In vivo, SU6656 administered prior to irradiation significantly promotes radiation-induced destruction of blood vessels within the tumor windows. It also facilitates tumor growth delay when administered during fractionated irradiation. [3]
References:
1. Blake RA, Broome MA, Liu X et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27.
2. Lannutti BJ, Blake N, Gandhi MJ et al. Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. Blood. 2005 May 15;105(10):3875-8.
3. Cuneo KC, Geng L, Tan J et al. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1197-203.
Cas No. | 330161-87-0 | SDF | |
化学名 | (Z)-2-hydroxy-N,N-dimethyl-3-((4,5,6,7-tetrahydro-1H-indol-2-yl)methylene)-3H-indole-5-sulfonamide | ||
Canonical SMILES | CN(S(C1=CC(/C(C(O)=N2)=C([H])/C(N3)=CC4=C3CCCC4)=C2C=C1)(=O)=O)C | ||
分子式 | C19H21N3O3S | 分子量 | 371.45 |
溶解度 | ≥ 18.55mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6922 mL | 13.4608 mL | 26.9215 mL |
5 mM | 0.5384 mL | 2.6922 mL | 5.3843 mL |
10 mM | 0.2692 mL | 1.3461 mL | 2.6922 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。